Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 and PD-L2 peptide vaccination in untreated chronic lymphocytic leukemia
2018-004869-14Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Feb 2019
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-L1 long1 peptide vaccine and PD-L2 Long201 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Herlev Hospital. Primary endpoint: Responses to the vaccine according to IW-CLL response criteria. Started Feb 2019; status: completed.
02
Drugs
PD-L1 long1 peptide vaccinePD-L2 Long201
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2018-004869-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004869-14.